According to FutureWise analysis the market for asthma and COPD drugs in 2023 is US$ 38.04 billion, and is expected to reach US$ 55.6 billion by 2031 at a CAGR of 4.90%.
The hyper-responsiveness of the airways results in wheezing, breathlessness, chest tightness, and coughing. Comparatively to other obstructive lung diseases, asthma is largely reversible. The biggest risk factor for asthma is allergies. Aside from irritants and exercise, asthma may also be triggered by cold air, animals, and dust. COPD, or chronic obstructive pulmonary disease, results in restricted airflow that cannot be fully reversed. There are two types of chronic obstructive pulmonary disease: emphysema and chronic bronchitis. Emphysema is a disease that damages alveoli while chronic bronchitis results from chronic inflammation. Most COPD cases are caused by smoking tobacco. The risk of COPD is also increased by passive smoking, occupational exposure, and ambient air pollution. Asthma and COPD can be diagnosed using X-rays, sputum eosinophils, and nitric oxide tests. Theophylline, inhaled corticosteroids, leukotriene modifiers, and inhaled corticosteroids are effective treatments for asthma and COPD. Acute respiratory attacks can be controlled by short-acting beta agonists and anticholinergic drugs. The Asthma and COPD Drugs market is expected to witness growth over the forecast period due to factors such as the growing prevalence of COPD and Asthma patients, pipeline products, government initiatives, and the rise in health awareness. Asthma and Chronic Obstructive Pulmonary Disease Drugs Market growth is mainly driven by the rise in asthma and COPD prevalence. New products launches in the global Asthma and Chronic Obstructive Pulmonary Disease Drugs Market are also anticipated to contribute to the market's growth.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Asthma And COPD Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Asthma And COPD Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.